Why Health Care's Future Is All About Value

Episode Summary

Executive Summary: Goldman Sachs researchers argue healthcare stocks have held up despite Washington uncertainty because most of the sector’s market cap is driven by drug and product companies whose earnings are less exposed to ACA reform. The real risks and opportunities lie in drug pricing, tax reform, and the shift toward value-based reimbursement, which could reshape pricing, M&A, and winners across pharma, hospitals, managed care, and health-tech.

Main Topics: Policy uncertainty has not derailed healthcare equities (Priority: 5/5): Despite the ACA repeal effort collapsing and ongoing Washington noise, healthcare became the second-best performing S&P group in 2017 because investors had feared worse outcomes on drug pricing and reform than materialized. Drug pricing as the main near-term overhang (Priority: 5/5): The speakers describe drug pricing as a decades-old bipartisan issue that intensified with high-profile drugs and congressional scrutiny. Companies are already self-policing through slower price increases and greater payer engagement. Corporate tax reform and repatriation as an M&A catalyst (Priority: 5/5): Large pharma and biotech firms are sitting on more than $200 billion overseas. Broad tax reform or repatriation could unlock that cash and trigger a wave of consolidation and mega-deals. Value-based reimbursement and the move away from fee-for-service (Priority: 4/5): Healthcare reimbursement is gradually shifting toward paying for outcomes, lower-cost care settings, and reduced waste. ACOs, bundled payments, and outcomes-based drug contracts are early signs of this transition. Who wins and loses in a value-based system (Priority: 4/5): Hospitals that remain fee-for-service dependent may lag, while managed care firms, pharma innovators, health IT, and service enablers could benefit if they adapt to outcome-based models. Technology’s limited disruption but growing role (Priority: 3/5): Traditional tech has not transformed healthcare as it has other sectors, largely because healthcare is fragmented and regulated. Still, data, analytics, AI, EMRs, and consumer apps are becoming increasingly important. Innovation cycles remain the main driver for biopharma (Priority: 4/5): Despite pricing pressures, drug stocks still move on product cycles. Oncology, immunology, CAR-T, gene therapy, gene editing, and Alzheimer’s remain key areas of R&D and investment interest.

Key Arguments: Healthcare equity performance has been resilient because investors feared punitive reform and drug-pricing actions that largely did not materialize. ACA repeal uncertainty matters less to the bulk of investable healthcare than to the public debate, because most market cap sits in product/therapeutic companies, not hospitals. Drug pricing remains the sector’s central policy risk, but the leaked executive order looked more market-based than punitive and may even help by curbing 340B discounts and speeding generics. Corporate tax reform matters because it could allow access to more than $200 billion in offshore cash and unlock large-scale pharma/biotech M&A. Self-regulation is already visible: branded-drug price growth has slowed and firms are experimenting with value-based contracts. Value-based reimbursement is being pushed by unsustainable healthcare cost growth and could shift incentives from volume to outcomes. ACOs and bundled payments are tangible examples of bipartisan support for outcome-based care. Hospitals and other fee-for-service models are most exposed, while managed care, health IT, and innovative pharma platforms are better positioned. Consumers are becoming more engaged because high-deductible plans shift more cost responsibility to patients. Healthcare technology disruption is slower than in other sectors, but EMRs, analytics, AI, and digital tools can help manage populations and improve efficiency.

Data Points: Healthcare sector performance: Second-best performing group in the S&P this year - Jamie Rubin says healthcare outperformed despite policy uncertainty. Offshore cash held by large-cap pharma/biotech: Over $200 billion - Used to explain why tax reform/repatriation could drive M&A. Branded drug price growth: 12% per year for the last five years - Bob Jones cites aggregate branded price increases before recent slowdown. Branded drug price growth year-to-date: High single digits - Shows self-policing by pharma pricing behavior. Generic drug pricing: High single-digit deflation - Bob notes this is more typical of commodity-like generics after a period of inflation. Healthcare share of GDP: Over 20% by 2025 - Used to frame the need for cost control and value-based reimbursement. Healthcare share of government budget: Nearly 40% by 2025 - Illustrates fiscal pressure from healthcare spending. US spending vs peers: 2.5x more per capita - Bob compares US healthcare spending to other industrialized nations. High-deductible plan penetration: About 30% of people today - Consumer cost-sharing has increased engagement with pricing. High-deductible plan growth: Tripled since 2010 - Shows the rise in consumer cost exposure. ACO scale: Over 900 systems - Bob references NextGen ACO and broader ACO adoption.

Pivotal Quotes: "healthcare has been the second best performing group in the S&P this year" — Jamie Rubin: On why the sector has held up despite Washington uncertainty. "my companies, the large-cap pharmaceutical companies, as well as large-cap biotech companies, are sitting with over $200 billion in cash outside the U.S." — Jamie Rubin: On why corporate tax reform could unleash M&A. "the structure of our insurance industry isn't quite ready for cures" — Jamie Rubin: On the challenge of pricing gene therapy, CAR-T, and other one-time treatments.

Implications: Investors should focus less on ACA headlines and more on drug pricing, tax reform, and reimbursement redesign. Winners will likely be firms that adapt to outcomes-based care, while fee-for-service laggards and inflexible pricing models face pressure.